[go: up one dir, main page]

AR045979A1 - Amidas heterociclicas - Google Patents

Amidas heterociclicas

Info

Publication number
AR045979A1
AR045979A1 ARP040101313A ARP040101313A AR045979A1 AR 045979 A1 AR045979 A1 AR 045979A1 AR P040101313 A ARP040101313 A AR P040101313A AR P040101313 A ARP040101313 A AR P040101313A AR 045979 A1 AR045979 A1 AR 045979A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
heteroaryl
cycloalkyl
halo
Prior art date
Application number
ARP040101313A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0301246A external-priority patent/SE0301246D0/xx
Priority claimed from SE0301305A external-priority patent/SE0301305D0/xx
Priority claimed from SE0400044A external-priority patent/SE0400044D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR045979A1 publication Critical patent/AR045979A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El presente se refiere a solvatos o sales solvatadas de dichos compuestos, procesos para su preparación, intermediarios utilizados en su preparación, composiciones farmacéuticas que contienen dichos compuestos y uso de éstos en tratamientos terapéuticos. Reivindicación 1: Un compuesto que tiene la fórmula (1), en donde: el anillo P es arilo C6-10, cicloalquilo C3-7, heteroarilo C5-6, en donde dicho anillo P puede estar fusionado con fenilo, heteroarilo C5-6, cicloalquilo C3-7 o heterocicloalquilo C3-7; R1 es NO2, NH2, halo, N(alquilo C1-6)2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, haloalquilo(C1-6)O, fenil alquilo(C0-6), heteroarilo(C5-6)alquilo(C0-6), cicloalquilo(C3-7)alquilo(C0-6), heterocicloalquilo(C3-7)alquilo(C0-6), alquilo(C1-6)Oalquilo(C0-6), alquilo(C1-6)Salquilo(C0-6) o alquilo(C1-6)Nalquilo(C0-6); n es 1, 2, 3, 4 ó 5; X es O o S, cuando: R3 es H, alquilo C1-6, haloalquilo C1-6, R5Oalquilo(C1-6), R5OCO, R5CO, NR5R6CO, NR5R6alquilo(C0-6), alquenilo(C2-6)Oalquilo(C0-6) o hidroxi alquilo(1-6); y R4 es cero; o X es N cuando: R3 es H, alquilo C1-6, yodoalquilo C1-6, bromoalquilo C1-6, cloroalquilo C1-6, alquilo(C1-6)Oalquilo(C0-6), R5Oalquilo(C1-6), R5CO, R5CO2, NR5R6CO, NR5R6alquilo(C0-6) o alquenilo(C2-6)Oalquilo(C0-6); R4 es H, alquilo C1-4, hidroxi alquilo(C1-6) o alquilo(C1-6)Oalquilo(C1-6); o X es N, cuando R3 es fluoroalquilo C1-6 o hidroxi alquilo(C1-2) y R4 es H; R5 y R6 se seleccionan de manera independiente entre H, alquilo C1-6, arilo C6-10, heteroarilo C5-6, alquilo(C1-4)SO2 y alquilo(C1-3)CO; R7 y R8 se seleccionan de manera independiente entre H, alquilo C1-6, halo, ciano, alquilo(C1-6)Oalquilo(C0-6), OH, NO2 y COR9, N(R9)2; R9 es H o alquilo C1-6; y en donde cualquier grupo alquilo, alquilOalquilo, haloalquilo, haloalquilO, fenilo, heteroarilo, cicloalquilo o heterocicloalquilo puede estar sustituido con uno o más A; y A es OH, NO2, R9CO, R9O(CO), N(R9)2, R9S, R9SO2, halo o alquilo(C1-6)Oalquilo(C0-6), o sales, solvatos o sales solvatadas de dicho compuesto.
ARP040101313A 2003-04-28 2004-04-19 Amidas heterociclicas AR045979A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0301246A SE0301246D0 (sv) 2003-04-28 2003-04-28 New compounds
SE0301305A SE0301305D0 (sv) 2003-05-05 2003-05-05 New compounds
SE0400044A SE0400044D0 (sv) 2004-01-12 2004-01-12 New compounds

Publications (1)

Publication Number Publication Date
AR045979A1 true AR045979A1 (es) 2005-11-23

Family

ID=33424839

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101313A AR045979A1 (es) 2003-04-28 2004-04-19 Amidas heterociclicas

Country Status (6)

Country Link
US (1) US20060223868A1 (es)
EP (1) EP1622884A1 (es)
JP (1) JP2006524687A (es)
AR (1) AR045979A1 (es)
TW (1) TW200512201A (es)
WO (1) WO2004096784A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046683A1 (en) 2003-10-07 2005-05-26 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
JP2007518816A (ja) * 2004-01-23 2007-07-12 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用
WO2006038871A1 (en) * 2004-10-08 2006-04-13 Astrazeneca Ab New hydroxymethylbenzothiazoles amides
US7875627B2 (en) * 2004-12-07 2011-01-25 Abbott Laboratories Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
SE0403117D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
SE0403118D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 2
SE0403171D0 (sv) * 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
CA2600933A1 (en) * 2005-02-28 2006-09-08 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007067757A2 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
EP1959944A1 (en) * 2005-12-15 2008-08-27 Shionogi Co., Ltd. A pharmaceutical composition comprising an amide derivative
JP2009527575A (ja) * 2006-02-23 2009-07-30 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド誘導体及び医薬組成物並びにそれらを使用する方法
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
US20090156598A1 (en) * 2007-12-17 2009-06-18 Lebsack Alec D Imidazolopyrimidine modulators of TRPV1
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
CN102977050B (zh) * 2012-11-20 2015-04-22 浙江工业大学 一种2-苯并噻唑二甲缩醛和2-苯并噻唑甲醛的合成方法
AU2016284942B2 (en) * 2015-06-22 2020-08-20 Actelion Pharmaceuticals Ltd NADPH oxidase 4 inhibitors
KR101844984B1 (ko) 2016-05-31 2018-04-03 한림대학교 산학협력단 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
CN115819371B (zh) * 2022-11-16 2024-05-14 新疆师范大学 一种苯并噻唑-2-甲醛及其衍生物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3506767A (en) * 1965-08-06 1970-04-14 Geigy Chem Corp Benzimidazole compositions and methods of use
US3711608A (en) * 1971-04-13 1973-01-16 Merck & Co Inc The treatment of pain, fever and inflammation with benzimidazoles
EP0023889B1 (de) * 1979-08-03 1983-03-09 Ciba-Geigy Ag Imino-isoindolinon-Metallkomplexe, Verfahren zu deren Herstellung, Verfahren zum Pigmentieren von hochmolekularem organischem Material und hochmolekulares organisches, einen solchen Metallkomplex enthaltendes Material
US4239887A (en) * 1979-10-31 1980-12-16 Usv Pharmaceutical Corporation Pyridothienotriazines
US4659738A (en) * 1985-02-15 1987-04-21 The United States Of America As Represented By The Secretary Of The Army Topical prophylaxis against schistosomal infections
EP0403885A1 (de) * 1989-06-20 1990-12-27 Bayer Ag Verwendung von 3-Hydroxybenzothiophenen zur Bekämpfung von Endoparasiten, neue 3-Hydroxybenzothiophene und Verfahren zu ihrer Herstellung
DE4237617A1 (de) * 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237557A1 (de) * 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
WO2002042273A2 (en) * 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US20040259875A1 (en) * 2001-07-31 2004-12-23 Takeshi Yura Amine derivatives
ES2338539T3 (es) * 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
US6974870B2 (en) * 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
AU2003252715B2 (en) * 2002-07-30 2009-06-04 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
WO2004056774A2 (en) * 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
ES2337254T3 (es) * 2003-02-14 2010-04-22 Glaxo Group Limited Derivados de carboxamida.
GB0324792D0 (en) * 2003-10-23 2003-11-26 Sterix Ltd Compound

Also Published As

Publication number Publication date
TW200512201A (en) 2005-04-01
EP1622884A1 (en) 2006-02-08
JP2006524687A (ja) 2006-11-02
WO2004096784A1 (en) 2004-11-11
US20060223868A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AR045979A1 (es) Amidas heterociclicas
AR044342A1 (es) Derivados de bencimidazol
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
CO6190512A2 (es) Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso
AR061374A1 (es) Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
UY26727A1 (es) Derivados de tropano útiles en terapia
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
AR071387A1 (es) Pirimidin-5-carboxamidas sustituidas
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR063906A1 (es) Compuestos quimicos derivados del indazol, una composicion farmaceutica y procesos de prpeparacion de los compuestos
AR035254A1 (es) Derivados fluorquinolonicos de oxazolidinonas utiles como antibacterianos, procedimiento para su obtencion y su utilizacion para la preparacion de una composicion farmaceutica
AR060267A1 (es) Tiazolil- dihidro -ciclopentapirazoles
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR060903A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
SE0403171D0 (sv) New compounds
AR039689A1 (es) Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
AR054363A1 (es) Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6

Legal Events

Date Code Title Description
FB Suspension of granting procedure